Seelos Therapeutics, Inc.
SEELDelisted Apr 4, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001017491
Seelos Therapeutics, Inc. was delisted on Apr 4, 2025; its insiders filed their last Form 4 on Mar 1, 2024; 23 institutions reported holding it in 13F filings for Q2 2024, worth $129.4K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Seelos Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Seelos Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Golembiewski Michael Joseph | Chief Financial Officer | 86,869 | Mar 1, 2024 | 0 |
| Mehra Raj | See Remarks | 185,142 | Jan 17, 2024 | 0 |
| Dalesandro Margaret | Director | 35,000 | Jan 8, 2024 | 0 |
| Pascoe Richard W | Director | – | Jan 8, 2024 | 0 |
| O'Connor Daniel J. | Director | 16,000 | Jan 8, 2024 | 0 |
| Lian Brian | Director | – | Jan 8, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 (view filing) | Mar 31 | Same day | Mehra RajSee Remarks | PPurchase | +66.7K | $0.85 | +$56.7K | +2.1%3.28M after | |
| May 27, 2022 (view filing) | May 26 | 1 day | Dalesandro MargaretDirector | PPurchase | +35.0K | $0.60 | +$21.0K | New position35.0K after | |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | O'Connor Daniel J.Director | PPurchase | +16.0K | $0.61 | +$9.76K | New position16.0K after | |
| Dec 1, 2023 (view filing) | Dec 1 | Same day | Mehra RajSee Remarks | PPurchase | +75.8K | $1.32 | +$100.0K | +69.3%185.1K after | |
| Dec 1, 2023 (view filing) | Dec 1 | Same day | Mehra RajSee Remarks | PPurchase | +75.8K | – | – | –75.8K after | Derivative |
| Dec 1, 2023 (view filing) | Nov 30 | 1 day | Golembiewski Michael JosephChief Financial Officer | PPurchase | +83.0K | $1.21 | +$100.4K | +2,405.8%86.5K after |